Cancer cells have found ways to evade one of the most promising new precision therapies, potentially affecting treatment strategies for thousands of patients with specific p53 mutations. This resistance mechanism could inform how to design better drugs that stay ahead of tumor evolution.
Clinical trials of rezatapopt, the first drug designed to reactivate the p53-Y220C mutant protein, revealed that tumors develop secondary mutations directly on the TP53 gene to escape treatment. Analysis of patient samples showed two distinct resistance pathways: mutations that completely destroy p53's DNA-binding function, and mutations that specifically block the drug from attaching to its target site on the Y220C cavity. These double mutations effectively render the reactivated p53 protein useless for triggering cancer cell death.
This represents a significant challenge for p53-targeted therapy development, as the Y220C mutation affects nearly 2% of all p53-mutant cancers—translating to tens of thousands of patients annually. The finding that resistance emerges through on-target mechanisms rather than bypass pathways suggests tumors are highly dependent on maintaining p53 dysfunction. However, this also means that simply reactivating mutant p53 may not be sufficient as a standalone approach. The molecular mapping of these resistance mutations provides a roadmap for developing next-generation compounds that could either prevent these secondary mutations or remain effective despite them. Given that p53 restoration has been a holy grail in cancer therapy for decades, understanding these resistance mechanisms early in clinical development could prove crucial for realizing the full potential of this therapeutic class.